Literature DB >> 7537960

Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.

T L Moser1, J J Enghild, S V Pizzo, M S Stack.   

Abstract

The present paper described interactions of urinary-type plasminogen activator (u-PA) with isolated protein components of the extracellular matrix (ECM) using kinetic and ligand-blotting analyses, as well as adhesion studies with u-PA-saturated U937 monocytic cells. Kinetic analyses showed that fibronectin and laminin were moderately effective at decreasing activation of plasminogen by u-PA (3-4-fold decrease in kcat/Km), while activation was stimulated slightly by collagen types I and IV (2-4-fold increase in kcat/Km). Ligand-blotting experiments using intact immobilized ECM proteins demonstrated that u-PA binds predominantly to vitronectin. This was supported by ELISA studies, which showed concentration dependent, saturable, reversible binding of u-PA to vitronectin (Kd,app. of 97 nM). Limited proteolysis of vitronectin followed by ligand-blotting analysis demonstrated u-PA binding to a specific vitronectin fragment (M(r) 49,000), and binding was shown to occur through the N-terminal fragment of u-PA. N-terminal sequence analysis indicated that this binding fragment of vitronectin originates with Thr-122 and comprises the hemopexin domain, including the heparin-binding region of the vitronectin molecule. Plasminogen activator inhibitor type I did not compete with u-PA for binding to vitronectin, suggesting both molecules may co-localize on vitronectin. In contrast, binding of u-PA to vitronectin was significantly inhibited by plasminogen, suggesting these molecules share a common binding site on vitronectin. In addition to in vitro studies, experiments were performed to assess the contribution of direct binding of u-PA to vitronectin on the adhesive behaviour of U937 cells. Binding of u-PA-saturated U937 cells to vitronectin was inhibited 66% by excess vitronectin, suggesting that direct binding of u-PA to vitronectin is the mechanism by which u-PA-dependent adhesion of U937 cells to vitronectin is mediated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537960      PMCID: PMC1136728          DOI: 10.1042/bj3070867

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin.

Authors:  R W Stephens; M Aumailley; R Timpl; T Reisberg; H Tapiovaara; H Myöhänen; J Murphy-Ullrich; A Vaheri
Journal:  Eur J Biochem       Date:  1992-08-01

Review 2.  Structure of vitronectin and its biological role in haemostasis.

Authors:  K T Preissner; D Jenne
Journal:  Thromb Haemost       Date:  1991-07-12       Impact factor: 5.249

3.  Selective enzyme purification by affinity chromatography.

Authors:  P Cuatrecasas; M Wilchek; C B Anfinsen
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

4.  Cellular receptor for urokinase-type plasminogen activator: protein structure.

Authors:  N Behrendt; M Ploug; E Rønne; G Høyer-Hansen; K Danø
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

5.  Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin.

Authors:  M S Stack; S V Pizzo
Journal:  J Biol Chem       Date:  1993-09-05       Impact factor: 5.157

6.  Heparin binding to the urokinase kringle domain.

Authors:  R W Stephens; A M Bokman; H T Myöhänen; T Reisberg; H Tapiovaara; N Pedersen; J Grøndahl-Hansen; M Llinás; A Vaheri
Journal:  Biochemistry       Date:  1992-08-25       Impact factor: 3.162

7.  The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

Authors:  D Seiffert; G Ciambrone; N V Wagner; B R Binder; D J Loskutoff
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

8.  Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.

Authors:  C Kost; W Stüber; H J Ehrlich; H Pannekoek; K T Preissner
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

9.  Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.

Authors:  D A Waltz; L Z Sailor; H A Chapman
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Domain structure and interactions of recombinant urokinase-type plasminogen activator.

Authors:  V Novokhatny; L Medved; A Mazar; P Marcotte; J Henkin; K Ingham
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

View more
  8 in total

1.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

3.  Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-beta 1.

Authors:  E Petzelbauer; J P Springhorn; A M Tucker; J A Madri
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

4.  A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Authors:  Thore Hillig; Lars H Engelholm; Signe Ingvarsen; Daniel H Madsen; Henrik Gårdsvoll; Jørgen K Larsen; Michael Ploug; Keld Danø; Lars Kjøller; Niels Behrendt
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

5.  S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.

Authors:  Kathleen M Devine; Yoel Smicun; Joanie Mayer Hope; David A Fishman
Journal:  Gynecol Oncol       Date:  2008-05-29       Impact factor: 5.482

6.  Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.

Authors:  P Franco; C Iaccarino; F Chiaradonna; A Brandazza; C Iavarone; M R Mastronicola; M L Nolli; M P Stoppelli
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

7.  Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.

Authors:  P Carmeliet; L Moons; M Dewerchin; S Rosenberg; J M Herbert; F Lupu; D Collen
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

8.  Material-driven fibronectin and vitronectin assembly enhances BMP-2 presentation and osteogenesis.

Authors:  Yinbo Xiao; Hannah Donnelly; Mark Sprott; Jiajun Luo; Vineetha Jayawarna; Leandro Lemgruber; P Monica Tsimbouri; R M Dominic Meek; Manuel Salmeron-Sanchez; Matthew J Dalby
Journal:  Mater Today Bio       Date:  2022-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.